Media Contact: Kaitlyn Rieper, Baylor University Media and Public Relations, 254-405-9110
Follow us on Twitter:
WACO, Texas (May 25, 2021) – Danielle Parrish, Ph.D., professor in the Diana R. Garland School of Social Work at Baylor University, has been awarded a $3.1 million grant by the National Institutes of Health to study the efficacy of risk reduction intervention efforts for young women age 14-17 in the juvenile justice system. The grant will be dispersed over five years, beginning May 2021. The project, titled CHOICES-TEEN: Efficacy of a Bundled Risk Reduction Intervention for Juvenile Justice Females, is an effort to fill gaps in care for at-risk young women in the juvenile justice system.
Share this article
Share this article
CLEVELAND, May 24, 2021 /PRNewswire/ KeyCorp (NYSE:KEY) announced that L. Waters will be joining the bank as General Counsel and Corporate Secretary effective July 6, 2021. Mr. Waters will lead Key s Law Group and serve as the company s senior legal officer. James is a seasoned legal professional with significant experience, having served as General Counsel and Corporate Secretary. His experience and skill-set in the critical areas of law and banking, will be essential as we continue to grow our company, said Chris Gorman, Chairman and Chief Executive Officer of KeyCorp.
James L. Waters
Mr. Waters brings more than 20 years of experience in corporate law with a focus on finance. Prior to joining Key, he served as General Counsel and Corporate Secretary at Cullen/Frost Bankers, Inc. Previously, Mr. Waters was a partner at Haynes and Boone, LLP where he spent eighteen years as a corporate lawyer representing banks and corporations.
Huntington s disease: A devastating neurologic disease spectrumlocalnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from spectrumlocalnews.com Daily Mail and Mail on Sunday newspapers.
email article
A cocktail of two monoclonal antibodies against COVID-19, casirivimab and imdevimab, reduced hospitalization and death by 71% versus placebo in high-risk, non-hospitalized patients, a researcher said.
COVID-19 hospitalization or all-cause mortality was significantly reduced through day 29 among high-risk patients who were randomized to the intervention (HR 0.29, 95% CI 0.17-0.49), reported Julie Philley, MD, of the University of Texas Health Science Center in Tyler.
Moreover, treatment with the intravenous monoclonal antibody combination was associated with 4 fewer days of symptom duration compared with placebo.
Casirivimab and imdevimab received emergency use authorization from the FDA in November, which was granted on the basis of phase I/II trial results in non-hospitalized adults with mild or moderate COVID-19. President Trump was treated with this therapy when he had COVID-19 in October 2020.
Share this article
TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/
Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo
Similar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower 1,200 mg dose to EUA
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of detailed results from the Phase 3 pivotal trial showing REGEN–COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19. These data were presented at the 2021 American Thoracic Society International Conference (ATS 2021) in the